Patheon overview - a look at what Lonza would gain

By Nick Taylor

- Last updated on GMT

Related tags: U.s. securities and exchange commission

With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.

JLL launched its takeover attempt in March but its $2 (€1.4) a share bid was trumped in August when Lonza tabled a $3.55 a share bid that values the company at $460m. At the end of August JLL allowed its offer to expire but is unwilling to sell its 57 per cent stake to Lonza.

In light of this struggle for control of the contract manufacturing organisation (CMO), Outsourcing-Pharma views Patheon’s growth and its global manufacturing capacity. Over the past 18 months the number of active projects at Patheon has increased by 31 per cent, rising to 392.

As shown in the graph below Patheon’s projects dipped in the first quarter of 2009, which was also a low point for many contract research organisation (CRO) revenues, but the upward trend resumed in the most recent financials.

These projects are being undertaken at 12 locations that Patheon operates in North America, including Puerto Rico, and Europe. Over the past few years Patheon has discontinued some operations but has retained an extensive manufacturing and development service capacity.

From these facilities Patheon can provide an array of services that include sterile manufacturing, high-potency products and production using solvents in explosion proof areas.


patheon key

Details of what services are provided at each facility, and the size of the site, can be viewed by clicking on the markers mapped below. Patheon’s 12 facilities and US and European headquarters are plotted on the map. The key shows the use of each facility.

All data was sourced on September 9 from Patheon’s website or filings with the US Securities and Exchange Commission (SEC).

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers